Also listed on Corvidia Therapeutics, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Jan 4, 2039 · High confidence
20-year base term ends Jan 4, 2039
Held by Novo Nordisk A/S
Filed Apr 26, 2019 as application 16/396,378 · Granted Jul 12, 2022
Base term, 20 years from filing
Today
2019
2039
Clock starts
Jan 4, 2019
Jan 4, 2019
Term ends
Jan 4, 2039
Jan 4, 2039
Granted
Jul 12, 2022
Jul 12, 2022
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 4, 2019, when application 16/240,670, the earliest non-provisional in its chain, was filed (this one was filed Apr 26, 2019) | Jan 4, 2039 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 4, 2039 | High confidence |
This family
| Application 16/240,670 | Abandoned not computed | not computed |
| US 11,384,143 | this patent Jan 2039 | Jan 2039 |
| Application 17/708,660 | Pending not computed | not computed |
| Application 17/991,880 | Pending not computed | not computed |
| Application 19/650,529 | Pending not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 29, 2019 Reel 49894, frame 18 | Devalaraja, Madhav N.; Davidson, Michael H.; Kakkar, Rahul | Corvidia Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jan 20, 2021 Reel 54965, frame 550 | Corvidia Therapeutics, Inc. | Novo Nordisk A/S | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2039
Term ends Jan 4, 2039. Maintenance fees still fall due before then
Citations
2
later US patents cite this one
That is above the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.